Medicine Matters Oncology

Research from three countries adds support for the use of a booster dose of vaccines against SARS-CoV-2 in people with cancer, especially those undergoing active anticancer treatment.

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

People with EGFR-positive non-small-cell lung cancer may benefit from individualized risk-profiling, say researchers who observed a high recurrence risk following resection but also identified a subgroup that may be cured without adjuvant osimertinib.

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.